{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:59:13Z","timestamp":1791838753428,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.it.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T16:09:11Z","timestamp":1735315751000},"page":"74-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics"],"prefix":"10.1016","volume":"46","author":[{"given":"Chih-Chun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4235","authenticated-orcid":false,"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2024.12.001_bb0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jdv.18851","article-title":"Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management","volume":"37","author":"Puig","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.it.2024.12.001_bb0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/ds.DS-D-24-00070","article-title":"Taiwanese Dermatological Association consensus recommendations for the diagnosis, treatment, and management of generalized pustular psoriasis","volume":"42","author":"Hsu","year":"2024","journal-title":"Dermatol. Sin."},{"key":"10.1016\/j.it.2024.12.001_bb0015","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.it.2024.12.001_bb0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.12.001_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0035","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.it.2024.12.001_bb0040","series-title":"FDA Approves the First Treatment Option for Generalized Pustular Psoriasis Flares in Adults","author":"Ingelheim","year":"2022"},{"key":"10.1016\/j.it.2024.12.001_bb0045","series-title":"SPEVIGO Prescribing Information","author":"Ingelheim","year":"2022"},{"key":"10.1016\/j.it.2024.12.001_bb0050","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.it.2024.12.001_bb0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0060","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/exd.14765","article-title":"Current management of generalized pustular psoriasis","volume":"32","author":"Kodali","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0065","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40257-022-00721-z","article-title":"New onset and exacerbations of psoriasis following COVID-19 vaccines: a systematic review","volume":"23","author":"Wu","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0070","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.it.2024.12.001_bb0075","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.it.2024.12.001_bb0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/DDDT.S194765","article-title":"Cathepsin G cleaves and activates IL-36\u03b3 and promotes the inflammation of psoriasis","volume":"13","author":"Guo","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.it.2024.12.001_bb0090","doi-asserted-by":"crossref","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36\u03b3","volume":"114","author":"Ainscough","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.it.2024.12.001_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/gb-2006-7-5-216","article-title":"An overview of the serpin superfamily","volume":"7","author":"Law","year":"2006","journal-title":"Genome Biol."},{"key":"10.1016\/j.it.2024.12.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.it.2024.12.001_bb0105","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2024.12.001_bb0110","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0115","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0120","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780242","article-title":"Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris","volume":"81","author":"Rottman","year":"2001","journal-title":"Lab. Investig."},{"key":"10.1016\/j.it.2024.12.001_bb0130","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jid.2021.12.021","article-title":"Transcriptomes of MPO-deficient patients with generalized pustular psoriasis reveals expansion of CD4(+) cytotoxic T cells and an involvement of the complement system","volume":"142","author":"Haskamp","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0135","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.4049\/jimmunol.1200385","article-title":"IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation","volume":"188","author":"Griffin","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0140","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.jid.2022.04.011","article-title":"A distinct immature low-density neutrophil population characterizes acute generalized pustular psoriasis","volume":"142","author":"Yu","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0150","doi-asserted-by":"crossref","first-page":"24880","DOI":"10.1038\/srep24880","article-title":"Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0155","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","article-title":"Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis","volume":"140","author":"Frey","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41419-018-0385-4","article-title":"Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases","volume":"9","author":"Sullivan","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.it.2024.12.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106045","article-title":"Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating I\u03baB\u03b6","volume":"79","author":"Tu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.it.2024.12.001_bb0170","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2024.12.001_bb0175","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/ijd.12894","article-title":"HLA-C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients","volume":"55","author":"Cardili","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1346-8138.15066","article-title":"Tumor necrosis factor \u2212238A is associated with pediatric-onset generalized pustular psoriasis in Han patients in Eastern China","volume":"46","author":"Zhao","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0185","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaad.2023.10.070","article-title":"MEFV variants are a predisposing factor for generalized pustular psoriasis","volume":"90","author":"Yoshikawa","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0190","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1346-8138.16700","article-title":"A homozygous loss-of-function variant in the MPO gene is associated with generalized pustular psoriasis","volume":"50","author":"Onitsuka","year":"2022","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jdermsci.2014.08.007","article-title":"Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with\/without psoriasis vulgaris","volume":"76","author":"Li","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.it.2024.12.001_bb0200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.it.2024.12.001_bb0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.2012.10953.x","article-title":"A novel IL36RN\/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult-onset generalized pustular psoriasis","volume":"167","author":"Sugiura","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0210","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1038\/jid.2013.214","article-title":"Mutations in IL36RN in patients with generalized pustular psoriasis","volume":"133","author":"K\u00f6rber","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10875-019-00622-7","article-title":"Interleukin-36 receptor antagonist deficiency (DITRA) with a novel IL36RN homozygous mutation c.200G>T (P.Cys67Phe) in a young Colombian woman","volume":"39","author":"Zea-Vera","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0220","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.343","article-title":"Targeted review of IL36RN mutations in patients with generalised pustular psoriasis","volume":"4","author":"Krueger","year":"2024","journal-title":"Skin Health Dis."},{"key":"10.1016\/j.it.2024.12.001_bb0230","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.12.001_bb0235","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/exd.14783","article-title":"Deficiency of interleukin-36 receptor antagonist (DITRA): an analysis of 58 Chinese patients in a tertiary hospital in Taiwan","volume":"32","author":"Hsieh","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamadermatol.2014.3002","article-title":"Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation","volume":"151","author":"Nakai","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0245","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/jid.2013.44","article-title":"Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis","volume":"133","author":"Navarini","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0250","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"M\u00f6ssner","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0255","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/jid.2012.490","article-title":"Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes","volume":"133","author":"Setta-Kaffetzi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2340\/00015555-2468","article-title":"Acrodermatitis continua of hallopeau with granuloma-like vegetation, osteolysis and IL36RN mutation","volume":"97","author":"Qi","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.it.2024.12.001_bb0265","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0270","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0275","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0280","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","article-title":"CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris","volume":"79","author":"Craiglow","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0285","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/jid.2015.288","article-title":"Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris","volume":"135","author":"Berki","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2014.02.006","article-title":"The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants","volume":"74","author":"Sugiura","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.it.2024.12.001_bb0295","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/ced.13926","article-title":"A novel CARD14 variant, homozygous c.526G>C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis","volume":"44","author":"Tobita","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0300","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-\u03baB, in psoriasis","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0305","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1042\/BCJ20160270","article-title":"Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-\u03baB activation","volume":"473","author":"Howes","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.it.2024.12.001_bb0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: a scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0315","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4103\/0366-6999.184470","article-title":"Tumor necrosis factor-alpha induced protein 3 interacting protein 1 gene polymorphisms and pustular psoriasis in Chinese Han population","volume":"129","author":"Han","year":"2016","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.it.2024.12.001_bb0320","first-page":"159","article-title":"Upregulation of tumor necrosis factor alpha-induced protein 3 interacting protein 1 mRNA in psoriasis vulgaris","volume":"13","author":"Wang","year":"2015","journal-title":"J. Deutschen Dermatol. Ges."},{"key":"10.1016\/j.it.2024.12.001_bb0325","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajhg.2020.06.020","article-title":"Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease","volume":"107","author":"Vergnano","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0330","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ajhg.2020.07.001","article-title":"Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases","volume":"107","author":"Haskamp","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0335","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood.V83.7.1935.1935","article-title":"Myeloperoxidase (MPO) gene mutation in hereditary MPO deficiency","volume":"83","author":"Kizaki","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.it.2024.12.001_bb0345","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/1346-8138.16081","article-title":"SERPINA1, generalized pustular psoriasis, and adult-onset immunodeficiency","volume":"48","author":"Kantaputra","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s10038-023-01139-z","article-title":"Newly revealed variants of SERPINA3 in generalized pustular psoriasis attenuate inhibition of ACT on cathepsin G","volume":"68","author":"Liu","year":"2023","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.it.2024.12.001_bb0350","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/genes14020266","article-title":"SERPINB3, adult-onset immunodeficiency, and generalized pustular psoriasis","volume":"14","author":"Kantaputra","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.it.2024.12.001_bb0355","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jid.2023.01.023","article-title":"Identification of the BTN3A3 gene as a molecule implicated in generalized pustular psoriasis in a Chinese population","volume":"143","author":"Zhang","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0360","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/sj.jid.5700822","article-title":"TNF-alpha gene promoter \u2013238G>A and \u2013308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis","volume":"127","author":"Li","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0365","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fimmu.2020.00716","article-title":"Gene-dose effect of MEFV gain-of-function mutations determines ex vivo neutrophil activation in familial Mediterranean fever","volume":"11","author":"Stoler","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2024.12.001_bb0370","first-page":"S113","article-title":"Increased serum concentrations of neutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations","volume":"33","author":"Lieber","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.it.2024.12.001_bb0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.12.001_bb0380","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/1346-8138.17471","article-title":"Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis","volume":"51","author":"Choon","year":"2024","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0385","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/1346-8138.16667","article-title":"Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study","volume":"50","author":"Yamanaka","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0390","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0395","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s13555-021-00666-x","article-title":"Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis","volume":"12","author":"Morita","year":"2022","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.it.2024.12.001_bb2005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb2010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0400","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamadermatol.2016.0751","article-title":"Therapeutic efficacy of interleukin 12\/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status","volume":"152","author":"Arakawa","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.12548","article-title":"Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations","volume":"170","author":"H\u00fcffmeier","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0425","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0430","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jdcr.2017.07.007","article-title":"Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities","volume":"3","author":"Jeon","year":"2017","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0435","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/ijdd.ijdd_23_22","article-title":"Novel use of tofacitinib in the recalcitrant adult generalized pustular psoriasis","volume":"8","author":"Shreya","year":"2022","journal-title":"Indian J. Drugs Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb2015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.it.2024.12.001_bb0445","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114099","article-title":"Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling","volume":"43","author":"Fields","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.12.001_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.12.001_bb0460","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0465","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0470","first-page":"e138","article-title":"English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis","volume":"50","author":"Saeki","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.it.2024.12.001_bb0475","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41419-023-05815-y","article-title":"TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis","volume":"14","author":"Lu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.it.2024.12.001_bb0480","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1080\/09546634.2021.1967265","article-title":"Downregulation of interleukin 36\u03b3 and its cleaver cathepsin G following treatment with narrow-band ultraviolet B phototherapy in psoriasis vulgaris","volume":"33","author":"El-Kalioby","year":"2022","journal-title":"J. Dermatol. Treat."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149062400303X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149062400303X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T05:10:01Z","timestamp":1742015401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149062400303X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S147149062400303X"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2024.12.001","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}